Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLAD mobile lifestyle education plus sodium oligomannate for mild to moderate cognitive impairment in Alzheimer's disease
ChiCTR2100053156Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Nov 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sodium oligomannate in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Patient quality of life and Caregiver care burden. Started Nov 2021; status: recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2100053156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053156.